Research progress of the selective sphingosine-1-phosphate receptor 1 agonists.
- Author:
Yu-Lin TIAN
1
;
Jing JIN
;
Xiao-Jian WANG
Author Information
1. Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory ofActive Substance Discovery and Druggability Evaluation, Beijing 100050, China.
- Publication Type:Journal Article
- MeSH:
Animals;
Fingolimod Hydrochloride;
Humans;
Immunosuppressive Agents;
pharmacology;
therapeutic use;
Lysophospholipids;
physiology;
Multiple Sclerosis;
drug therapy;
Propylene Glycols;
pharmacology;
therapeutic use;
Receptors, Lysosphingolipid;
agonists;
classification;
metabolism;
physiology;
Sphingosine;
analogs & derivatives;
pharmacology;
physiology;
therapeutic use;
Structure-Activity Relationship
- From:
Acta Pharmaceutica Sinica
2012;47(1):7-17
- CountryChina
- Language:Chinese
-
Abstract:
Sphingosine-1-phosphate (S1P) is a lysophospholipid signaling molecule that regulates important biological functions in both intracellular and extracellular compartments. It interacts with five G protein-coupled receptors subtypes (S1PR(1-5)) to generate multiple downstream signaling. Activation of S1PR1 has been validated to be involved in the process of immune modulation. Fingolimod (FTY720), the novel S1PR1 agonist, has been approved for the treatment of multiple sclerosis in clinical trials. The study towards discovery of selective S1PR1 agonists has become hot spot for immunological diseases. This article summarized the research progress of S1PR1 agonists, emphasizing their structure types, structure-activity relationship and direction of development.
